Radient Pharmaceuticals (RPC) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RPC Hot Sheet
Join SI Premium – FREE
Radient Pharmaceuticals (NYSE: RPC) reported Q3 EPS of $0.25, $0.01 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $88.9 million versus the consensus estimate of $94 million.
For earnings history and earnings-related data on Radient Pharmaceuticals (RPC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Inter Parfums (IPAR) Tops Q3 EPS by 33c ; Offers Guidance
- Deluxe Corp. (DLX) Tops Q3 EPS by 11c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
